Laser system for treatment of glaucoma gets European patent approval

Article

The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval.

The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval.

The technology is a CO2 laser-based system which enables the filtration procedure for the alleviation of Intra Ocular Pressure.

According to Dr. Ami Eya, CEO of Bio-Light,“The EPO approval will enable commercialization of our systems in a protected and proprietary environment. It was a short while ago when we received the CE mark of approval and we are currently preparing for the implementation of our systems in the European markets parallel to the implementation in the Far East markets which has already begun. We are continuing our process of achieving FDA approval and expect to begin clinical trials in the US shortly.”

Dr Joshua Degani, IOPtima CEO says, “Receiving the EPO approval is another important milestone for IOPtima which further validates and strengthens our position towards launching our product in Europe. Recently, we have obtained a CE mark of approval after successfully completing clinical testing in leading medical centres in Europe, Italy, Spain, and Russia. We believe that we can provide an effective and viable solution to millions of people suffering from this chronic eye disease that require constant treatment.”

It is estimated that by 2010, approximately 12 million people in Europe, will suffer from glaucoma. The cost of medication treatment of glaucoma, the currently most common form of treatment, is estimated to be above $3 billion every year worldwide.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.